BiondVax Pharmaceuticals Ltd. (BVXV)

NASDAQ: BVXV · Delayed Price · USD
1.26
-0.01 (-0.79%)
At close: May 25, 2022 4:00 PM
1.32
0.06 (4.76%)
After-hours:May 25, 2022 4:05 PM EDT

Company Description

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel.

The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals Logo
CountryIsrael
Founded2003
IndustryPharmaceuticals
SectorHealth Care
Employees15
CEORon Babecoff

Contact Details

Address:
Weizmann Science Park
Po Box 4143 14 Einstein Street, Ness Ziona 7403618
Israel
Phone972 8 930 2529
Websitebiondvax.com

Stock Details

Ticker SymbolBVXV
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyILS
CIK Code0001611747

Key Executives

NamePosition
Amir Reichman M.B.A., M.Sc.Chief Executive Officer and Director
Uri Ben-Or CPA, CPA, M.B.A., MBAChief Financial Officer
Elad Mark B.Sc., Eng., M.B.A.Chief Operating Officer
Dr. Tamar Ben-Yedidia Ph.D.Chief Scientist
Joshua E. Phillipson B.Sc., M.B.A.Director of Business Development and Investor Relations
Moran Ahdout Fruchter L.L.B.Chief of Staff
Dalit Weinstein FischerHead of Technical Research & Development

Latest SEC Filings

DateTypeTitle
May 18, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 13, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 12, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 8, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 4, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 4, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 28, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Jan 11, 2022SC 13D/AGeneral statement of acquisition of beneficial ownership
Jan 11, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 30, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings